GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Cyclically Adjusted Price-to-FCF

OCUL (Ocular Therapeutix) Cyclically Adjusted Price-to-FCF : (As of Jan. 19, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocular Therapeutix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ocular Therapeutix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Cyclically Adjusted Price-to-FCF Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocular Therapeutix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocular Therapeutix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted Price-to-FCF falls into.



Ocular Therapeutix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ocular Therapeutix's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Ocular Therapeutix's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.219/133.0289*133.0289
=-0.219

Current CPI (Sep. 2024) = 133.0289.

Ocular Therapeutix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.284 99.070 -0.381
201503 -0.339 99.621 -0.453
201506 -0.424 100.684 -0.560
201509 -0.396 100.392 -0.525
201512 -0.369 99.792 -0.492
201603 -0.379 100.470 -0.502
201606 -0.406 101.688 -0.531
201609 -0.330 101.861 -0.431
201612 -0.333 101.863 -0.435
201703 -0.587 102.862 -0.759
201706 -0.521 103.349 -0.671
201709 -0.564 104.136 -0.720
201712 -0.371 104.011 -0.475
201803 -0.369 105.290 -0.466
201806 -0.341 106.317 -0.427
201809 -0.291 106.507 -0.363
201812 -0.343 105.998 -0.430
201903 -0.455 107.251 -0.564
201906 -0.458 108.070 -0.564
201909 -0.379 108.329 -0.465
201912 -0.410 108.420 -0.503
202003 -0.368 108.902 -0.450
202006 -0.260 108.767 -0.318
202009 -0.202 109.815 -0.245
202012 -0.092 109.897 -0.111
202103 -0.201 111.754 -0.239
202106 -0.246 114.631 -0.285
202109 -0.155 115.734 -0.178
202112 -0.192 117.630 -0.217
202203 -0.229 121.301 -0.251
202206 -0.138 125.017 -0.147
202209 -0.181 125.227 -0.192
202212 -0.231 125.222 -0.245
202303 -0.302 127.348 -0.315
202306 -0.283 128.729 -0.292
202309 -0.094 129.860 -0.096
202312 -0.254 129.419 -0.261
202403 -0.259 131.776 -0.261
202406 -0.154 132.554 -0.155
202409 -0.219 133.029 -0.219

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ocular Therapeutix  (NAS:OCUL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ocular Therapeutix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix Business Description

Industry
Traded in Other Exchanges
Address
15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730